SCHEMBL1390797

SCHEMBL1390797

COc1ccc2nc(C(C)NC(C)=O)oc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
PPARD Q03181 1/20 0.50
PPARA Q07869 1/20 0.50
ACACB O00763 4/20 0.47
POLB P06746 2/20 0.46
APP P05067 1/20 0.45
MAPT P10636 1/20 0.44
TP53 P04637 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
CNR1 P21554 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1390754 0.90 RAB9A (0.60) NPC1RAB9AKMT2AMEN1PPARD
SCHEMBL1391568 0.84 MAPT (0.48) NPC1RAB9AKMT2AMEN1POLB
SCHEMBL1390812 0.83 PPARD (0.44) NPC1RAB9AKMT2AMEN1PPARD
SCHEMBL10239190 0.83 NPC1 (0.45) NPC1RAB9AKMT2AMEN1ACACB
SCHEMBL12432312 0.82 PPARD (0.47) PPARDPPARAACACBPOLBAPP
SCHEMBL10239413 0.82 MAPT (0.48) NPC1RAB9AKMT2AMEN1POLB
SCHEMBL1390974 0.80 TP53 (0.52) NPC1PPARDPPARAACACBAPP
SCHEMBL1390894 0.80 MAPT (0.46) ACACBPOLBMAPTTP53
SCHEMBL1391059 0.79 TP53 (0.53) NPC1PPARDPPARAACACBPOLB
SCHEMBL1390576 0.76 RAB9A (0.56) NPC1RAB9AKMT2AMEN1PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB NPC1 978/4885RAB9A 3698/4885KMT2A 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.